Gamma Secretase (EC 3.4.23.) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Gamma Secretase (EC 3.4.23.) – Pipeline Review, H2 2017’, provides in depth analysis on Gamma Secretase (EC 3.4.23.) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Oncology and Ear Nose Throat Disorders under development targeting Gamma Secretase (EC 3.4.23.).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astellas Pharma Inc

Bristol-Myers Squibb Co

Critical Outcome Technologies Inc

Lipopharma Therapeutics SL

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

Pfizer Inc

Stemline Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Gamma Secretase (EC

3.4.23.) - Overview 7

Gamma Secretase (EC

3.4.23.) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 14

Gamma Secretase (EC

3.4.23.) - Therapeutics Assessment 16

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Gamma Secretase (EC

3.4.23.) - Companies Involved in Therapeutics Development 22

Astellas Pharma Inc 22

Bristol-Myers Squibb Co 22

Critical Outcome Technologies Inc 22

Lipopharma Therapeutics SL 23

Merck & Co Inc 23

NeuroGenetic Pharmaceuticals Inc 24

Pfizer Inc 24

Stemline Therapeutics Inc 25

Takeda Pharmaceutical Co Ltd 25

Gamma Secretase (EC

3.4.23.) - Drug Profiles 27

AS-2715348 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

BMS-932481 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

BMS-986133 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

GSI-34 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

LP-226A1 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

LY-3056480 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

NGP-328 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NGP-555 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

nirogacestat - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Peptides to Inhibit PSEN1 for Alzheimer’s Disease - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PF-06648671 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SL-301 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SL-302 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Gamma Secretase (EC

3.4.23.) - Dormant Products 49

Gamma Secretase (EC

3.4.23.) - Discontinued Products 51

Gamma Secretase (EC

3.4.23.) - Product Development Milestones 52

Featured News & Press Releases 52

Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 52

Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial 52

Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer’s Disease 52

Jun 16, 2014: Prof. G.L. Nicolson and Prof. R.M. Epand join Lipopharma's SAB 53

Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease 53

Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimer’s disease 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Investigation by Universities/Institutes, H2 2017 14

Products under Investigation by Universities/Institutes, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by Astellas Pharma Inc, H2 2017 22

Pipeline by Bristol-Myers Squibb Co, H2 2017 22

Pipeline by Critical Outcome Technologies Inc, H2 2017 23

Pipeline by Lipopharma Therapeutics SL, H2 2017 23

Pipeline by Merck & Co Inc, H2 2017 24

Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2017 24

Pipeline by Pfizer Inc, H2 2017 25

Pipeline by Stemline Therapeutics Inc, H2 2017 25

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 26

Dormant Products, H2 2017 49

Dormant Products, H2 2017 (Contd..1), H2 2017 50

Discontinued Products, H2 2017 51

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports